Lung Cancer News and Research

Latest Lung Cancer News and Research

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

New compound may halt drug-resistant lung cancer

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.

24 Dec 2009

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.

23 Dec 2009

Scientists use DNA sequence to characterize genome rearrangement in breast cancer samples

The first detailed search of breast cancer genomes to uncover genomic rearrangements is published today. The team characterised the ways in which the human genome is broken and put back together in 24 cases of breast cancer.

23 Dec 2009

Latest diagnosis and treatment of small and non-small cell lung cancer

Under the auspices of the 12th International Symposium on Special Aspects in Radiotherapy 2008 in Berlin, acknowledged experts presented their perspectives on small and non-small cell lung cancer, reflecting the latest standards and engaging in controversies in the diagnosis and treatment of this disease.

23 Dec 2009

RPC declares 2010 business plans

Radient Pharmaceuticals Corporation, a US-based vertically integrated pharmaceutical company, whose wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI) announced today it 2010 Business Plan. This forecast is based upon the Company raising at least $2 million during the first half of 2010.

23 Dec 2009

Poniard Pharmaceuticals sells common shares for $6.5 million

Poniard Pharmaceuticals today announced the sale of 3,489,728 of its common shares to Azimuth Opportunity Ltd. for net proceeds of approximately $6.5 million, or approximately $1.87 per share, under its existing committed equity financing facility with Azimuth.

23 Dec 2009

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention.

22 Dec 2009

Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported

Bryan Oncor reports the results of a Phase I trial of its targeted radiopharmaceutical therapy using Re-88 P2045, a radiolabeled synthetic peptide, for the treatment of advanced lung cancer.

21 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

21 Dec 2009

United States Congress approves additional $15 million in research funding for lung cancer

Today, the United States Congress approved an additional $15 million in research funding for lung cancer as part of the fiscal year 2010 Department of Defense (DOD) Appropriations package.

20 Dec 2009

Rosetta Genomics announces third-quarter 2009 financial results

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2009 and provided a business update.

18 Dec 2009

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom.

18 Dec 2009

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Yesterday, an advisory committee to the Food and Drug Administration voted against the approval of Tarceva(R) (erlotinib) as maintenance treatment for advanced lung cancer patients.

18 Dec 2009

Study findings highlight the need to develop specific health policies to address social disparities

Racial and ethnic disparities in cancer survival are greatest for cancers that can be detected early and treated successfully, including breast and prostate cancer, according to a study by researchers at Columbia University's Mailman School of Public Health and Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital.

18 Dec 2009

Brachytherapy for lung cancer

A 58-year-old man who lives in Corona, Queens came to the emergency room of New York Hospital Queens (NYHQ) with extreme pain and tingling in his left arm. Although he did not realize it at the time, he had lung cancer. Recently, he made medical history as the first patient in the United States to be treated for lung cancer through the use of radioactive pellets placed directly in the tumor, and today his recovery is going well. Known as brachytherapy, this treatment approach is commonly used to treat prostate cancer.

18 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

18 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

Lung Cancer News and Research

Latest Lung Cancer News and Research

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

New compound may halt drug-resistant lung cancer

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Scientists use DNA sequence to characterize genome rearrangement in breast cancer samples

Latest diagnosis and treatment of small and non-small cell lung cancer

RPC declares 2010 business plans

Poniard Pharmaceuticals sells common shares for $6.5 million

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

Results from Phase I trial of Bryan Oncor's targeted radiopharmaceutical therapy reported

Clarient announces acquisition of Applied Genomics

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

United States Congress approves additional $15 million in research funding for lung cancer

Rosetta Genomics announces third-quarter 2009 financial results

Cost of Avastin a deterrent for non-small-cell lung cancer treatment

FDA advisory committee votes against approval of Tarceva for lung cancer treatment

Study findings highlight the need to develop specific health policies to address social disparities

Brachytherapy for lung cancer

Phase 2 clinical study of STA-9090 in NSCLC initiated

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Lung Cancer News and Research

Latest Lung Cancer News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in